Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of LY3323795 in Healthy Subjects
NCT02989389Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3323795 in Alzheimer's disease (AD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. Started Dec 2016; status: completed.
02
Drugs
LY3323795
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02989389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02989389.